: Tuberculosis (TB) is an infectious disease that annually affects millions of people, and resistance to available antibiotics has exacerbated this situation. Another notable characteristic of Mycobacterium tuberculosis, the primary causative agent of TB, is its ability to survive inside macrophages, a key component of the immune system. In our quest for an effective and safe treatment that facilitates the targeted delivery of antibiotics to the site of infection, we have proposed a nanotechnology approach based on an iron chelator. Iron chelators are the primary mechanism by which bacteria acquire iron, a metal essential for their metabolism. Four liposomes were synthesized and characterized using the dynamic light scattering technique (DLS), nanoparticle tracking analysis (NTA), and transmission electron microscopy (TEM). All of these methods revealed the presence of spherical particles, approximately 200 nm in size. NTA indicated a concentration of around 1011 particles/mL. We also developed and validated a high-performance liquid chromatography method for quantifying Moxifloxacin to determine encapsulation efficiency (EE) and release profiles (RF). The EE was 51.31 % for LipMox and 45.76 % for LipIchMox. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) confirmed the phagocytosis of liposomal vesicles by macrophages. Functionalizing liposomes with iron chelators can offer significant benefits for TB treatment, such as targeted drug delivery to intracellular bacilli through the phagocytosis of liposomal particles by cells like macrophages.

Maringolo Ribeiro, C., Augusto Roque-Borda, C., Carolina Franzini, M., Fernanda Manieri, K., Manaia Demarqui, F., Leite Campos, D., Temperani Amaral Machado, R., Cristiane Da Silva, I., Tavares Luiz, M., Delello Di Filippo, L., Bento Da Silva, P., Cristina Oliveira Da Rocha, M., Nair Báo, S., Masci, D., Fernandes, G. F. S., Castagnolo, D., Chorilli, M., Rogério Pavan, F., Liposome-siderophore conjugates loaded with moxifloxacin serve as a model for drug delivery against Mycobacterium tuberculosis, <<INTERNATIONAL JOURNAL OF PHARMACEUTICS>>, 2024; 655 (655): 1-14. [doi:10.1016/j.ijpharm.2024.124050] [https://hdl.handle.net/10807/270996]

Liposome-siderophore conjugates loaded with moxifloxacin serve as a model for drug delivery against Mycobacterium tuberculosis

Masci, Domiziana;
2024

Abstract

: Tuberculosis (TB) is an infectious disease that annually affects millions of people, and resistance to available antibiotics has exacerbated this situation. Another notable characteristic of Mycobacterium tuberculosis, the primary causative agent of TB, is its ability to survive inside macrophages, a key component of the immune system. In our quest for an effective and safe treatment that facilitates the targeted delivery of antibiotics to the site of infection, we have proposed a nanotechnology approach based on an iron chelator. Iron chelators are the primary mechanism by which bacteria acquire iron, a metal essential for their metabolism. Four liposomes were synthesized and characterized using the dynamic light scattering technique (DLS), nanoparticle tracking analysis (NTA), and transmission electron microscopy (TEM). All of these methods revealed the presence of spherical particles, approximately 200 nm in size. NTA indicated a concentration of around 1011 particles/mL. We also developed and validated a high-performance liquid chromatography method for quantifying Moxifloxacin to determine encapsulation efficiency (EE) and release profiles (RF). The EE was 51.31 % for LipMox and 45.76 % for LipIchMox. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) confirmed the phagocytosis of liposomal vesicles by macrophages. Functionalizing liposomes with iron chelators can offer significant benefits for TB treatment, such as targeted drug delivery to intracellular bacilli through the phagocytosis of liposomal particles by cells like macrophages.
2024
Inglese
Maringolo Ribeiro, C., Augusto Roque-Borda, C., Carolina Franzini, M., Fernanda Manieri, K., Manaia Demarqui, F., Leite Campos, D., Temperani Amaral Machado, R., Cristiane Da Silva, I., Tavares Luiz, M., Delello Di Filippo, L., Bento Da Silva, P., Cristina Oliveira Da Rocha, M., Nair Báo, S., Masci, D., Fernandes, G. F. S., Castagnolo, D., Chorilli, M., Rogério Pavan, F., Liposome-siderophore conjugates loaded with moxifloxacin serve as a model for drug delivery against Mycobacterium tuberculosis, <<INTERNATIONAL JOURNAL OF PHARMACEUTICS>>, 2024; 655 (655): 1-14. [doi:10.1016/j.ijpharm.2024.124050] [https://hdl.handle.net/10807/270996]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/270996
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact